IL6 and neoplasm: Similarly, high IL-6 has been shown to be a poor prognostic marker to ICI response in multiple tumor cohorts, and preclinical data suggest a potential dual benefit of IL-6 blockade, including improved tumor control and reduced toxicity (46–53, 77, 78).